Home > Boards > US Listed > Biotechs > Jounce Therapeutics Inc. (JNCE)

JNCE - Huge Buyers Hit Market At Different

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TopMarketGainers Member Profile
 
Followed By 27
Posts 1,022
Boards Moderated 1
Alias Born 04/28/19
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/7/2019 12:08:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/7/2019 6:43:51 AM
Jounce Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire Inc. - 11/7/2019 6:30:00 AM
Jounce Therapeutics to Present Safety and Preliminary Efficacy Data on JTX-4014 and a Trials in Progress Poster for the Vopra... GlobeNewswire Inc. - 11/5/2019 8:05:00 AM
Jounce Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Thursday, November 7, 2019 GlobeNewswire Inc. - 10/31/2019 8:00:05 AM
Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Ca... GlobeNewswire Inc. - 10/1/2019 6:01:00 PM
Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary GlobeNewswire Inc. - 9/17/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 8:52:48 AM
Jounce Therapeutics to Present at Upcoming Investor Conferences in September GlobeNewswire Inc. - 8/28/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 11:25:18 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 7:17:18 AM
Jounce Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire Inc. - 8/7/2019 6:30:00 AM
Jounce Therapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019 GlobeNewswire Inc. - 7/31/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/23/2019 4:05:41 PM
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation GlobeNewswire Inc. - 7/23/2019 4:00:00 PM
Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small ... GlobeNewswire Inc. - 6/18/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 10:33:44 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 10:33:19 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 10:33:04 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 10:32:43 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 10:32:18 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 10:31:58 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 10:31:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/13/2019 10:27:57 AM
Jounce Therapeutics to Present at Upcoming Investor Conferences in June GlobeNewswire Inc. - 6/11/2019 8:00:00 AM
TopMarketGainers   Tuesday, 07/30/19 09:10:47 PM
Re: None
Post # of 12 
JNCE - Huge Buyers Hit Market At Different Trading Price

Jounce Therapeutics Inc (NASDAQ: JNCE ) shares are trading higher after the company announced an amended licensing agreement with Celgene Corporation (NASDAQ: CELG ), the latter of which has agreed to be acquired by Bristol-Myers Squibb Co (NYSE: BMY ). (Source: https://finance.yahoo.com/news/know-joun...)

Jounce Therapeutics , Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

SHORT INTEREST
456.94K 06/28/19

P/E Ratio (with extraordinary items)
-5.04

Analyst Target Price $12.50

Recommendation: HOLD



Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009,
we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!

IHUB Board: https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist